Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILB-2109 + Toripalimab in Advanced Solid Malignancies
NCT05955105Phase 2Recruiting
- Sponsor
- Innolake Biopharm
- Start
- Jul 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ILB-2109 in head and neck cancer (HNC), Cervical Cancer (CC), endometrial cancer (EC), triple-negative breast cancer (TNBC), ovarian cancer, sponsored by Innolake Biopharm. Started Jul 2023; status: recruiting.
02
Drugs
ILB-2109
03
Conditions
head and neck cancer (HNC)Cervical Cancer (CC)endometrial cancer (EC)triple-negative breast cancer (TNBC)ovarian cancer
Beyond the preview
Go deeper on NCT05955105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955105.